EUVIMEDEUVIMED entdecken
Crossref

TAL1 Suppresses High-Grade Serous Ovarian Cancer Progression by Transcriptionally Inhibiting TPI1-Mediated Glycolysis

Nan Zhao, Yu Wang, Wei Gao, Chunhe Zhou

The Tohoku Journal of Experimental Medicine · 2026

DOI: 10.1620/tjem.2025.j169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Tohoku Journal of Experimental Medicine, 2026. Verfasst von Nan Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gynecology Ward 1, Harbin Medical University Affiliated Cancer Hospital. Hauptthemen laut MEDLINE: Glycolysis, Ovarian Neoplasms, Transcription, Genetic, Disease Progression. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-grade serous ovarian cancer (HGSOC) is often accompanied by a poor prognosis, which urges the development of new therapeutic approaches. This study attempts to explore the role of T-cell acute lymphocytic leukemia Protein 1 (TAL1)-triosephosphate isomerase 1 (TPI1) mechanism in glycolysis-driven progression of HGSOC. Bioinformatics analysis identified TPI1 as upregulated in HGSOC tissues. This was confirmed by RT-qPCR and Western blotting (WB) in HGSOC cells. Functional assays, including EdU, colony formation, and Transwell, showed that TPI1 knockdown or knockout suppressed HGSOC cell proliferation, migration, invasion, and glycolysis. TAL1 was found to be downregulated in HGSOC cells, and dual-luciferase reporter and chromatin immunoprecipitation (ChIP) assays confirmed that TAL1 directly repressed TPI1 transcription by binding to its promoter. Importantly, overexpression of TAL1 suppressed HGSOC progression and glycolysis, whereas combined overexpression of TPI1 rescued these effects. Blocking glycolysis attenuates the effect of TPI1 overexpression on malignant proliferation and metastatic-like behavior in HGSOC cells. These findings demonstrate that TAL1 inhibits HGSOC progression by blocking glycolysis through transcriptional repression of TPI1, suggesting a potential therapeutic target for intervention in HGSOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlycolysisOvarian NeoplasmsTranscription, GeneticDisease ProgressionT-Cell Acute Lymphocytic Leukemia Protein 1Triose-Phosphate IsomeraseCystadenocarcinoma, SerousFemaleHumansCell ProliferationGene Expression Regulation, NeoplasticCell Line, TumorCell MovementNeoplasm GradingPromoter Regions, GeneticNeoplasm Invasiveness

Stichwörter der Autor:innen

TAL1TPI1glycolysishigh-grade serous ovarian cancertranscriptional repression

Substanzen

T-Cell Acute Lymphocytic Leukemia Protein 1Triose-Phosphate IsomeraseTAL1 protein, human

Autor:innen und Institutionen

  • Gynecology Ward 1, Harbin Medical University Affiliated Cancer Hospital.
  • Breast Internal Medicine 1, Harbin Medical University Affiliated Cancer Hospital.
  • Chest Radiotherapy Ward 1, Harbin Medical University Affiliated Cancer Hospital.

Zitieren

APA

Zhao, N., Wang, Y., Gao, W., & Zhou, C. (2026). TAL1 Suppresses High-Grade Serous Ovarian Cancer Progression by Transcriptionally Inhibiting TPI1-Mediated Glycolysis. The Tohoku Journal of Experimental Medicine. https://doi.org/10.1620/tjem.2025.j169

Vancouver

Zhao N, Wang Y, Gao W, Zhou C. TAL1 Suppresses High-Grade Serous Ovarian Cancer Progression by Transcriptionally Inhibiting TPI1-Mediated Glycolysis. The Tohoku Journal of Experimental Medicine. 2026. doi:10.1620/tjem.2025.j169

BibTeX
@article{Zhao2026,
  author = {Zhao, Nan and Wang, Yu and Gao, Wei and Zhou, Chunhe},
  title = {TAL1 Suppresses High-Grade Serous Ovarian Cancer Progression by Transcriptionally Inhibiting TPI1-Mediated Glycolysis},
  journal = {The Tohoku Journal of Experimental Medicine},
  year = {2026},
  doi = {10.1620/tjem.2025.j169}
}
Kostenlos starten →